Spyre Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Spyre Therapeutics Inc's ROI in the third quarter of 2026?
Spyre Therapeutics Inc recorded a cumulative net loss of $-264 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -29.11%.

Within the Healthcare sector 345 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 2091 to 3511.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	84.24 %	59.68 %	26.27 %	20.01 %	28.42 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	1,093	1,134	679	719	458
Return On Investment (TTM)	-29.11 %	-23.93 %	-31.04 %	-29.11 %	-30.28 %
SYRE's Overall Ranking	# 3511	# 2091	# 3099	# 3259	#
Seq. Investment Change TTM	21.22 %	29.35 %	8.43 %	8.37 %	5.06 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-264	-179	-179	-155	-149

SYRE Company Profile >> Back to SYRE Roi Comparisons >> See Annual SYRE Return On Investment

Return On Investment SYRE's Ranking
Within:	No.
Industry	# 127
Sector	# 346
Overall	# 3511

Return On Investment Statistics
High	Average	Low
-23.93 %	-93.42 %	-600.72 %
(Jun 30 2026)		(Jun 30 2023)

Financial Statements
Spyre Therapeutics Inc's III. Quarter Investments	$ 1,093 Millions	SYRE's Balance sheet
Spyre Therapeutics Inc's III. Quarter Income	$ -96 Millions	Quarterly SYRE's Income Statement
SYRE's Income by Division		See SYRE's Income by Division

SYRE Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	719	554	310	56	90
Y / Y Investment Growth	29.7 %	78.92 %	448.58 %	-37.08 %	-38.16 %
Net Income in Millions	-155	-208	-339	-84	-66
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-21.58 %	-37.52 %	-109.33 %	-148.38 %	-73.29 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SYRE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SYRE's Competitors
Subscribers only: Roi for Spyre Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for SYRE's Customers

Other Ratios
SYRE's Roa	SYRE's Inventory Turnover Ratio	SYRE's Growth Rates	SYRE's Dividend Statistics
	SYRE's Profitability Ratios	SYRE's Asset Turnover Ratio	SYRE's Dividend Growth
SYRE's Roe	SYRE's Valuation Ratios	SYRE's Financial Strength Ratios	SYRE's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector

ROI

Date modified: 2026-11-04T15:26:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.